Compare DexCom, Inc. (DXCM) vs Invesco Preferred ETF (PGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Invesco Preferred ETF — how do they compare? DexCom, Inc. trades at $85.15 (market cap $31.86B), while Invesco Preferred ETF trades at $10.02 (market cap $3.60B). The key difference: DexCom, Inc. is far larger — about 8.8× Invesco Preferred ETF's market cap, and DexCom, Inc. is trading nearer its 52-week high, Invesco Preferred ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Invesco Preferred ETF for 94 Days on average.
| DXCM | PGX | |
|---|---|---|
Market Cap | $31.86B | $3.60B |
Volume | 3,607,070 | 5,986,026 |
Sector | Health | — |
52-Week High | $92.34 | $11.61 |
52-Week Low | $54.84 | $9.97 |
Typical Hold Time | 62 Days | 94 Days |
Enterprise Value | $31.32B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $84.3, up 1.09% today, with a bearish technical signal despite strong fundamentals. The company reported Q2 2026 EPS of $0.70, beating estimates, continuing a trend of earnings outperformance. Revenue growth is robust, with 2025 revenue reaching $4.66 billion and net income margin improving to 20.12%. Analyst consensus is strongly bullish with an 80.77% buy rating and a $95.07 price target, suggesting significant upside from current levels.
The outlook for DXCM is positive driven by expansion in continuous glucose monitoring for Type 2 diabetes, as highlighted in recent company reports. Key risks include competitive pressures and reimbursement challenges. With solid cash flow generation and institutional support, the stock presents a growth opportunity, though investors should monitor execution against high expectations.
PGX trades at $9.97, down 0.89% today, with technical indicators showing a bearish trend from moving averages but oversold signals from the RSI. The stock faces pressure amid mixed sentiment, with key support and resistance levels clustered around $10. Recent corporate actions include scheduled dividends for July and September 2026, but fundamental data such as P/E and profitability metrics are unavailable for analysis.
The outlook for PGX is cautious due to the bearish technical setup and lack of current fundamental visibility. Risks include potential volatility near the $10 level and dependence on future financial disclosures to assess valuation. Investment opportunity hinges on upcoming earnings reports clarifying growth and margins, while sentiment remains divided amid limited recent news coverage.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Invesco Preferred ETF
The fund generally will invest at least 80% of its total assets in the components of the index. Strictly in accordance with its guidelines and mandated procedures, ICE Data Indices, LLC selects securities for the index, which is a market capitalization-weighted index designed to measure the performance of the fixed rate US dollar-denominated preferred securities market.
Read more on PGX →
